Advertisement

Non-Hormonal Medications and Chronic Diseases

  • Patricia F. Coogan
Chapter

Abstract

This chapter explores the relation between breast cancer risk and the use of non-hormonal medications and chronic diseases. Many drugs and diseases have been linked with breast cancer in case reports and epidemiologic studies. This chapter covers those major medications and diseases where there is adequate epidemiologic evidence for evaluation.

Keywords

Breast Cancer Systemic Lupus Erythematosus Breast Cancer Risk Multiple Sclerosis Patient Systemic Lupus Erythematosus Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Achiron A, Barak Y, Gail M, Mandel M, Pee D et al (2005) Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Cancer Res Treat 89:265–270PubMedCrossRefGoogle Scholar
  2. ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981–2997CrossRefGoogle Scholar
  3. Amato MP, Pracucci G, Ponziani G, Siracusa G, Fratiglioni L, Amaducci L (1993) Long-term safety of azathioprine therapy in multiple sclerosis. Neurology 43:831–833PubMedGoogle Scholar
  4. Arun B, Miller A, Isaacs K, Saxton KP, Brown P, Elledge R (2005) Accquisition of breast tissue in a biomarker modulation study using bexarotene in women at high risk of breast cancer. J Clin Oncol ASCO Annucal Meeting Proceedings. 23(16S):1002Google Scholar
  5. Ashbury FD, Madlensky L, Raich P, Thompson M, Whitney G et al (2003) Antidepressant prescribing in community cancer care. Support Care Cancer 11:278–285PubMedGoogle Scholar
  6. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L et al (2005) Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64:1421–1426PubMedCrossRefGoogle Scholar
  7. Baron JA (2003) Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res 37:1–24PubMedCrossRefGoogle Scholar
  8. Beck P, Wysowski DK, Downey W, Butler-Jones D (2003) Statin use and the risk of breast cancer. J Clin Epidemiol 56:280–285PubMedCrossRefGoogle Scholar
  9. Bergasa NV (1998) Primary biliary cirrhosis in patients with breast cancer: studying the link. Med Hypotheses 50:465–472PubMedCrossRefGoogle Scholar
  10. Bernatsky S, Boivin JF, Joseph L, St Pierre Y, Moore A, Rajan R, Clarke A (2002) Prevalence of factors influencing cancer risk in women with lupus: social habits, reproductive issues, and obesity. J Rheumatol 29:2551–2554PubMedGoogle Scholar
  11. Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A et al (2005a) An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 52:1481–1490PubMedCrossRefGoogle Scholar
  12. Bernatsky S, Ramsey-Goldman R, Clarke A (2005b) Exploring the links between systemic lupus erythematosus and cancer. Rheum Dis Clin Am 31:387–402CrossRefGoogle Scholar
  13. Blais L, Desgagne A, LeLorier J (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160:2363–2368PubMedCrossRefGoogle Scholar
  14. Bonanni B, Lazzeroni M, Veronesi U (2007) Synthetic retinoid fenretinide in breast cancer chemoprevention. Expert Rev Anticancer Ther 7:423–432PubMedCrossRefGoogle Scholar
  15. Bordeleau L, Pritchard K, Goodwin P, Loprinzi C (2007) Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. Clin Ther 29:230–241PubMedCrossRefGoogle Scholar
  16. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR (2004) The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer 100:2308–2316PubMedCrossRefGoogle Scholar
  17. Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR, Daling JR (2007) Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 16:416–421PubMedCrossRefGoogle Scholar
  18. Brandes LJ, Arron RJ, Bogdanovic RP, Tong J, Zaborniak CL et al (1992) Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 52:3796–3800PubMedGoogle Scholar
  19. Brtko J (2007) Role of retinoids and their cognate nuclear receptors in breast cancer chemoprevention. Cent Eur J Public Health 15:3–6PubMedGoogle Scholar
  20. Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC et al (2006) Statin use and breast cancer: prospective results from the Women’s Health Initiative. J Natl Cancer Inst 98:700–707PubMedCrossRefGoogle Scholar
  21. Cauley JA, Zmuda JM, Lui LY, Hillier TA, Ness RB et al (2003) Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt) 12:749–756CrossRefGoogle Scholar
  22. Chubak J, Buist DS, Boudreau DM, Rossing MA, Lumley T, Weiss NS (2007) Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat 112:123–132PubMedCrossRefGoogle Scholar
  23. Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G (1996) Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 46:1607–1612PubMedGoogle Scholar
  24. Coogan PF (2006) Review of the epidemiological literature on antidepressant use and breast cancer risk. Expert Rev Neurother 6:1363–1374PubMedCrossRefGoogle Scholar
  25. Coogan PF, Rosenberg L, Strom BL (2007) Statin use and the risk of 10 cancers. Epidemiology 18:213–219PubMedCrossRefGoogle Scholar
  26. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294:47–55PubMedCrossRefGoogle Scholar
  27. Cotterchio M, Kreiger N, Darlington G, Steingart A (2000) Antidepressant medication use and breast cancer risk. Am J Epidemiol 151:951–957PubMedGoogle Scholar
  28. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160–1167PubMedCrossRefGoogle Scholar
  29. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S et al (2005) Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 103:1122–1128PubMedCrossRefGoogle Scholar
  30. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM (2006) Statins and cancer risk: a meta-analysis. JAMA 295:74–80PubMedCrossRefGoogle Scholar
  31. Daling JR (1996) Calcium channel blockers and cancer: is an association biologically plausible?. Am J Hypertens 9:713–714PubMedCrossRefGoogle Scholar
  32. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5:930–942PubMedCrossRefGoogle Scholar
  33. Didham RC, Reith DM, McConnell DW, Harrison KS (2005) Antibiotic exposure and breast cancer in New Zealand. Breast Cancer Res Treat 92:163–167PubMedCrossRefGoogle Scholar
  34. Duncan RE, El-Sohemy A, Archer MC (2007) Statins and cancer. Epidemiology 18:520PubMedCrossRefGoogle Scholar
  35. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA (1996) Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 88:988–993PubMedCrossRefGoogle Scholar
  36. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE (2005) Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 165:2264–2271PubMedCrossRefGoogle Scholar
  37. Extermann M (2007) Interaction between comorbidity and cancer. Cancer Control 14:13–22PubMedGoogle Scholar
  38. Felmeden DC, Lip GY (2001) Antihypertensive therapy and cancer risk. Drug Saf 24:727–739PubMedCrossRefGoogle Scholar
  39. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL (1997) Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 80:1438–1447PubMedCrossRefGoogle Scholar
  40. Friedman GD, Oestreicher N, Chan J, Quesenberry CP Jr, Udaltsova N, Habel LA (2006) Antibiotics and risk of breast cancer: up to 9 years of follow-up of 2.1 million women. Cancer Epidemiol Biomarkers Prev 15:2102–2106PubMedCrossRefGoogle Scholar
  41. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP et al (2005) Cancer risk among statin users: a population-based cohort study. Int J Cancer 114:643–647PubMedCrossRefGoogle Scholar
  42. Friis S, Sorensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL et al (2001) Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 92:2462–2470PubMedCrossRefGoogle Scholar
  43. Friis S, Thomassen L, Sorensen HT, Tjonneland A, Overvad K, Cronin-Fenton DP et al (2008) Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev 17:88–96PubMedCrossRefGoogle Scholar
  44. Fryzek JP, Poulsen AH, Lipworth L, Pedersen L, Norgaard M et al (2006) A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat 97:231–236PubMedCrossRefGoogle Scholar
  45. Garcia Rodriguez LA, Gonzalez-Perez A (2005) Use of antibiotics and risk of breast cancer. Am J Epidemiol 161:616–619PubMedCrossRefGoogle Scholar
  46. Gierach GL, Lacey JV, Schatzkin A, Leitzmann MF, Richesson D, Hollenbeck AR et al (2008) Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res 10:R38 (doi: 10.1186/bcr2089)PubMedCrossRefGoogle Scholar
  47. Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN (2007) Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol 166:1150–1158PubMedCrossRefGoogle Scholar
  48. Goldman MB (1990) Thyroid diseases and breast cancer. Epidemiol Rev 12:16–28PubMedGoogle Scholar
  49. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R (2003) Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 3:28PubMedCrossRefGoogle Scholar
  50. Gonzalez-Perez A, Ronquist G, Garcia Rodriguez LA (2004) Breast cancer incidence and use of antihypertensive medication in women. Pharmacoepidemiol Drug Saf 13:581–585PubMedCrossRefGoogle Scholar
  51. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ (2004) The risk of cancer in users of statins. J Clin Oncol 22:2388–2394PubMedCrossRefGoogle Scholar
  52. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO et al (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307–311PubMedCrossRefGoogle Scholar
  53. Grossman E, Messerli FH, Goldbourt U (2001) Antihypertensive therapy and the risk of malignancies. Eur Heart J 22:1343–1352PubMedCrossRefGoogle Scholar
  54. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL et al (2003) Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res 63:6096–6101PubMedGoogle Scholar
  55. Horwitz RI, Feinstein AR (1985) Exclusion bias and the false relationship of reserpine and breast cancer. Arch Intern Med 145:1873–1875PubMedCrossRefGoogle Scholar
  56. Howel D, Metcalf JV, Gray J, Newman WL, Jones DE, James OF (1999) Cancer risk in primary biliary cirrhosis: a study in northern England. Gut 45:756–760PubMedCrossRefGoogle Scholar
  57. Hudson AG, Gierach GL, Modugno F, Simpson J, Wilson JW, Evans RW et al (2008) Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17:680–687PubMedCrossRefGoogle Scholar
  58. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE (2007) A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 99:608–615PubMedCrossRefGoogle Scholar
  59. Johnson TW, Anderson KE, Lazovich D, Folsom AR (2002) Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 11:1586–1591PubMedGoogle Scholar
  60. Kaye JA, Jick H (2004) Statin use and cancer risk in the General Practice Research Database. Br J Cancer 90:635–637PubMedCrossRefGoogle Scholar
  61. Kaye JA, Jick H (2005) Antibiotics and the risk of breast cancer. Epidemiology 16:688–690PubMedCrossRefGoogle Scholar
  62. Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84:1188–1192PubMedCrossRefGoogle Scholar
  63. Knekt P, Adlercreutz H, Rissanen H, Aromaa A, Teppo L, Heliovaara M (2000) Does antibacterial treatment for urinary tract infection contribute to the risk of breast cancer?. Br J Cancer 82:1107–1110PubMedCrossRefGoogle Scholar
  64. Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B (2008) Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Br Cancer Res Treat 109:573–579CrossRefGoogle Scholar
  65. Largent JA, McEligot AJ, Ziogas A, Reid C, Hess J et al (2006) Hypertension, diuretics and breast cancer risk. J Hum Hypertens 20:727–732PubMedCrossRefGoogle Scholar
  66. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT et al (1998) Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?. Lancet 352:179–184PubMedCrossRefGoogle Scholar
  67. Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR (2003) Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65–79 years. Cancer 98:1504–1513PubMedCrossRefGoogle Scholar
  68. Lindberg H, Nielsen D, Jensen BV, Eriksen J, Skovsgaard T (2004) Angiotensin converting enzyme inhibitors for cancer treatment?. Acta Oncol 43:142–152PubMedCrossRefGoogle Scholar
  69. Lindgren A, Pukkala E, Tuomilehto J, Nissinen A (2007) Incidence of breast cancer among postmenopausal, hypertensive women. Int J Cancer 121:641–644PubMedCrossRefGoogle Scholar
  70. Lindholm LH, Anderson H, Ekbom T, Hansson L, Lanke J et al (2001) Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet 358:539–544PubMedCrossRefGoogle Scholar
  71. Mangiapane S, Blettner M, Schlattmann P (2008) Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoepidemiol Drug Safety 17:115–124CrossRefGoogle Scholar
  72. Manjer J, Kaaks R, Riboli E, Berglund G (2001) Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucose metabolism: a prospective study within the Malmo Preventive Project. Eur J Cancer Prev 10:33–42PubMedCrossRefGoogle Scholar
  73. Marshall SF, Bernstein L, Anton-Culver H, Deapen D, Horn-Ross PL et al (2005) Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 97:805–812PubMedCrossRefGoogle Scholar
  74. McKenna MC, Zevon MA, Corn B, Rounds J (1999) Psychosocial factors and the development of breast cancer: a meta-analysis. Health Psychol 18:520–531PubMedCrossRefGoogle Scholar
  75. McTiernan A, Wu L, Barnabei VM, Chen C, Hendrix S, Modugno F et al (2008) Relation of demographic factors, menstrual history, reproduction and medication use to sex hormone levels in postmenopausal women. Breast Cancer Res Treat 108:217–231PubMedCrossRefGoogle Scholar
  76. Meier CR, Derby LE, Jick SS, Jick H (2000) Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 160:349–353PubMedCrossRefGoogle Scholar
  77. Meier CR, Schmitz S, Jick H (2002) Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 22:303–309PubMedCrossRefGoogle Scholar
  78. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32A:1753–1757PubMedCrossRefGoogle Scholar
  79. Michels KB, Rosner BA, Walker AM, Stampfer MJ, Manson JE et al (1998) Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the Nurses' Health Study. Cancer 83:2003–2007PubMedCrossRefGoogle Scholar
  80. Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE et al (2003) Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care 26:1752–1758PubMedCrossRefGoogle Scholar
  81. Midgard R, Glattre E, Gronning M, Riise T, Edland A, Nyland H (1996) Multiple sclerosis and cancer in Norway. A retrospective cohort study. Acta Neurol Scand 93:411–415PubMedCrossRefGoogle Scholar
  82. Moller H, Kneller RW, Boice JD Jr, Olsen JH (1991) Cancer incidence following hospitalization for multiple sclerosis in Denmark. Acta Neurol Scand 84:214–220PubMedCrossRefGoogle Scholar
  83. National Cancer Institute (1998) http://www.cancer/clinicaltrials.gov. Accessed 7 Nov 2007
  84. Nielsen NM, Rostgaard K, Rasmussen S, Koch-Henriksen N, Storm HH et al (2006) Cancer risk among patients with multiple sclerosis: a population-based register study. Int J Cancer 118:979–984PubMedCrossRefGoogle Scholar
  85. Nijhawan PK, Therneau TM, Dickson ER, Boynton J, Lindor KD (1999) Incidence of cancer in primary biliary cirrhosis: the Mayo experience. Hepatology 29:1396–1398PubMedCrossRefGoogle Scholar
  86. Peeters PH, van Noord PA, Hoes AW, Fracheboud J, Gimbrere CH, Grobbee DE (2000) Hypertension and breast cancer risk in a 19-year follow-up study (the DOM cohort). Diagnostic investigation into mammarian cancer. J Hypertens 18:249–254PubMedCrossRefGoogle Scholar
  87. Pocobelli G, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, Egan KM (2008) Statin use and risk of breast cancer. Cancer 112:27–33PubMedCrossRefGoogle Scholar
  88. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T et al (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62:632–635PubMedGoogle Scholar
  89. Ron E, Doody MM, Becker DV, Brill AB, Curtis RE et al (1998) Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 280:347–355PubMedCrossRefGoogle Scholar
  90. Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD et al (1998) Calcium channel blockers and the risk of cancer. JAMA 279:1000–1004PubMedCrossRefGoogle Scholar
  91. Seeger H, Wallwiener D, Mueck AO (2003) Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes 111:47–48PubMedCrossRefGoogle Scholar
  92. Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S (2007) Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 115:27–33PubMedCrossRefGoogle Scholar
  93. Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J et al (2006) Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54:2757–2764PubMedCrossRefGoogle Scholar
  94. SHEP Cooperative Research Group (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265:3255–3264CrossRefGoogle Scholar
  95. Simon MS, Tang MT, Bernstein L, Norman SA, Weiss L et al (2002) Do thyroid disorders increase the risk of breast cancer?. Cancer Epidemiol Biomarkers Prev 11:1574–1578PubMedGoogle Scholar
  96. Singh-Ranger G, Salhab M, Mokbel K (2008) The role of cyclooxygenase-2 in breast cancer: review. Cancer Epidemiol Biomarkers Prev 109:189–198Google Scholar
  97. Smyth PP (2000) Autoimmune thyroid disease and breast cancer: a chance association?. J Endocrinol Invest 23:42–43PubMedGoogle Scholar
  98. Sorensen HT, Skriver MV, Friis S, McLaughlin JK, Blot WJ, Baron JA (2005) Use of antibiotics and risk of breast cancer: a population-based case-control study. Br J Cancer 92:594–596PubMedGoogle Scholar
  99. Taketo MM (1998) Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90:1529–1536PubMedCrossRefGoogle Scholar
  100. Tamim HM, Hanley JA, Hajeer AH, Boivin J, Collet J (2008) Risk of breast cancer in relation to antibiotic use. Pharmarcoepidemiol Drug Safety 17:144–150CrossRefGoogle Scholar
  101. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL et al (2004) Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291:2433–2440PubMedCrossRefGoogle Scholar
  102. Thomas E, Brewster DH, Black RJ, Macfarlane GJ (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88:497–502PubMedCrossRefGoogle Scholar
  103. Tworoger S, Eliassen A, Rosner B, Sluss P, Hankinson S (2004) Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 64:6814–6819PubMedCrossRefGoogle Scholar
  104. Tzioufas AG, Voulgarelis M (2007) Update on Sjogren’s syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Pract Res Clin Rheumatol 21:989–1010PubMedCrossRefGoogle Scholar
  105. Uray IP, Brown PH (2006) Prevention of breast cancer: current state of the science and future opportunities. Expert Opin Invest Drugs 15:1583–1600CrossRefGoogle Scholar
  106. Van der Knaap R, Siemes C, Coebergh JW, van Duijn CM, Hofman A, Stricker BHC (2008) Renin-angiotensin system inhibitors, antiotensin-I-converting enzyme gene iinsertion/deletion polymorphism, and cancer: The Rotterdam Study. Cancer 112:748–757CrossRefGoogle Scholar
  107. Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, Taplin SH (2004) Antibiotic use in relation to the risk of breast cancer. JAMA 291:827–835PubMedCrossRefGoogle Scholar
  108. Veronesi U, De Palo G, Marubini E, Costa A, Formelli F et al (1999) Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91:1847–1856PubMedCrossRefGoogle Scholar
  109. Volpe DA, Ellison CD, Parchment RE, Grieshaber CK, Faustino PJ (2003) Effects of amitriptyline and fluoxetine upon the in vitro proliferation of tumor cell lines. J Exp Ther Oncol 3:169–184PubMedCrossRefGoogle Scholar
  110. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB et al (1996) Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98:671–679PubMedCrossRefGoogle Scholar
  111. Weiss SR, McFarland BH, Burkhart GA, Ho PT (1998) Cancer recurrences and secondary primary cancers after use of antihistamines or antidepressants. Clin Pharmacol Ther 63:594–599PubMedGoogle Scholar
  112. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B (2005) Diabetes mellitus and breast cancer. Lancet Oncol 6:103–111PubMedCrossRefGoogle Scholar
  113. Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56:2886–2895PubMedCrossRefGoogle Scholar
  114. Xue F, Michels KB (2007) Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 86(suppl):823S–835SGoogle Scholar
  115. Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L (2005) Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited. Am J Epidemiol 162:165–170PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Slone Epidemiology CenterBoston UniversityBostonUSA

Personalised recommendations